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Abstract. Guiding legislation and associated bureaucracy for the ethical review of clinical trials observational
studies and food related research play an important role in the competitiveness of a nation in the face of tough
global competition to attract sponsors and investigators. This is of particular relevance in the case of multicentre trials and multidisciplinary research. Accordingly, in this report we tried to gather in-depth knowledge
of the current role and practices of ethics committees nationwide in both clinical and research settings. This
mini-review aims to describe the formulation and organization of ethical committees in Italy in order to provide a focus for deliberations on ethical issues in medical and scientific research in line with human rights, as
set out in the European Union charter. Furthermore, we evaluated the impact of an institution’s ethical committee intervention on reducing the time required to obtain an opinion from Research Ethics Committees by
guiding investigators in addressing ethical issues in their proposed studies. (www.actabiomedica.it)
Key words: Ethics Committee, Italy, Clinical trials, Observational study, Food related research, risks, ethics
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Introduction
Bioethics is a discipline dealing with ethical issues
in biomedical and biological research. With the ongoing advance of science and technology, the concerns
related to safety and security of human subjects have
increased tremendously. This requires that biomedical
research and health care activities, as well as proposed
scientific activities, must be reviewed by independent
authorities according to national, supranational and
international legislation. This required the establishment of ethical committees (ECs) to ensure that research and health care practices are carried out in an
ethically acceptable manner.
Ethics Committees (ECs) are independent, multidisciplinary, non-profit bodies. They are constituted
to evaluate clinical experimentation and research involving human subjects and routine patient care from
an ethical and scientific point of view, in order to ensure that these abide by the ethical standards set by
national and international guidelines (1). These committees are deployed to analyse the ethical concerns
related to patient care or research involving human
subjects (2). Depending upon their specific roles, the
ethical committees are of two types: Research Ethics
Committees (RECs), and Clinical Ethics Committees (CECs) (3,4). RECs deal with the evaluation of
research projects and protocols so as to protect the
rights, safety and wellbeing of human subjects involved in clinical research and trials, while CECs are
responsible for addressing the ethical issues related to
daily clinical practice, bioethics training, and the development of ethical guidelines (3,4).
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least in Europe and other western countries, the core
of a robust infrastructure which monitors and reviews
research projects. Several supporting initiatives have
been also promoted e.g. by the World Health Organization, in establishing the Global Network of WHO
Collaborating Centres for Bioethics (https://www.
who.int/ethics/partnerships/global_network/en/).
The history of the formation of ethics committees
dates back to the 1960s, when the US National Institutes of Health established a policy regarding the ethical review of all research projects submitted to the US
Public Health Service for funding (5). This initial act
stimulated debates which took place on ethical concerns regarding clinical studies involving human subjects. These debates resulted in the National Research
Act 1974, with the subsequent establishment of the Institutional Review Board (IRB) system to oversee clinical research practices involving humans (6). Further
developments led to the establishment of a National
Commission for the Protection of Human Subjects of
Biomedical and Behavioural Sciences, to safeguard individuals participating in clinical trials and to develop
guidelines for biomedical research. The Commission
mandated that all research protocols involving humans
must seek approval from the IRB. At the same time,
the President’s Commission for the Study of Ethical
Problems in Medicine and Behavioural Research was
established to examine ethical issues involving health
care services and professionals, which led to organization of clinical ethics committees (CECs) for addressing ethical issues of clinical practice (2,6).

Research ethics in Europe
History and importance of Ethical Committees
The establishment of ethical committees has been
a relatively short journey. In the early second half
of the 20th century, review bodies started to emerge,
mainly as a form of self-regulation within the medical
profession, and often in an ad-hoc form in response to
specific problems. However, in past decades Research
Ethics Committees (RECs) have been established in
most European countries and worldwide as permanent
and independent bodies (4,5). As such they form, at

Meanwhile in 1964 in Helsinki, Finland, the
World Medical Association adopted a declaration on
research ethics as a reaction to malpractices revealed
during the Nuremberg trials (7). Since then, this declaration has been extensively reviewed. However, the
main focus and the central ideas remain unchanged
(8). The declaration sets out ethical principles for biomedical practices and research involving human subjects, the basic principle being the prioritization of the
safety and well-being of human subjects, followed by
principles for medical research and, additionally, for
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medical research combined with medical care (8). The
EU regulatory framework emphasizes the explicit EU
commitment to human rights, illustrated by the Oviedo Convention (9) which was adopted by the Council
of Europe in 1997, and also by the European Charter of Fundamental Rights (10). This convention addresses the ethical issues raised in research within the
framework of human rights protection (9). It sets out
principles to ensure the welfare of human beings, and
to ensure informed consent and privacy (9).
Ethics is given the highest priority in EU funded
research: all the activities carried out under Horizon
2020 must comply with ethical principles and relevant
national, EU and international legislation (see e.g.
https://ec.europa.eu/programmes/horizon2020/en/
h2020-section/ethics) The most common ethical issues
include those relating to the involvement of children,
patients, vulnerable populations, the use of human embryonic stem cells, privacy and data protection issues,
research on animals and non-human primates, misuse/
malevolent use, food security and safety, impact on the
environment, etc. It also includes the avoidance of any

breach of research integrity, which means, in particular,
avoiding fabrication, falsification, plagiarism or other
research misconduct. The EU ensures that the research
it funds complies with core ethical values in all phases
of research. Even though research ethics are more established in medical research, it is equally pivotal for
all scientific domains. For that reason, professional and
academic associations formulate policies and guidelines with ethics codes, adapted to their specific research domains.
Recently, the EU has implemented its Regulation
536/2014 on clinical trials (11), aiming to increase the
efficiency and rapidity of the procedures for approving
trials, simplifying sponsors’ obligations and guaranteeing public access to trial-related data. The regulations
attribute to the ECs the freedom to organize their
activities in accordance with each EU member state’s
legislation. De facto, Regulation 536/2014 has reduced
the number of ECs and increased the workload in clinical trials, and the activity addressing ethical issues in
every-day clinical practice is further diminished (12).

Table 1. Number of Research Ethic Committees (RECs) and accountability of RECs at different levels in EU countries (13)
Country

Number of RECs

Type of REC-Accountable to whom

UK

80+51 for non clinical trial of an
investigational medicinal product.

All RECs—UK Ethics Committee Authority or the body they
have nominated
University REC—medical faculty

Austria

26

Hospital REC—hospital head
Outside hospital—regional government

215

Central REC—government
University REC—medical faculty
Outside hospital—institute where situated

Bulgaria

103

Central REC on drug trials—Ministry of Health
Central REC on research ethics— Ministry of Education and
Science
Local REC—central REC

Cyprus

3+1 central

Central REC—Ministry of Health
Local—none

Czech Republic

9 multicentre, 100 local

Central REC—none
Local REC—none

Denmark

11

Central REC—none
Regional REC—central REC

Belgium

(continued on next page)
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Table 1 (continued). Number of Research Ethic Committees (RECs) and accountability of RECs at different levels in EU countries (13)
Country

Number of RECs

Type of REC-Accountable to whom

Estonia

2

Regional RECs—none

Finland

5+1 central

Central REC—Ministry of Health
Regional REC—board of the hospital district

France

40

Central REC—none
Institutional REC—none
Local REC—none

Germany

53

Central REC—Federal Chancellor
Local REC—institution where situated

Greece

One in each region and hospital+1
central

Central REC—Ministry of Health
Regional and local RECs—none

Hungary

Several regional and local+1 central

Central REC—Ministry of Health
Regional REC—central REC
Local REC—regional REC

Ireland

13

Local REC—Ethics Committees Supervisory Body

Italy

90

National bioethics committee—Prime Minister
Central REC—Ministry of Health
Local REC—none

Latvia

4 regional+1 central

Central REC—none
Regional REC—central REC

Lithuania

3

Central REC—Ministry of Health
Regional REC—central REC

Luxembourg

1

No information available

Malta

3 local+1 central

Central REC—university
Local RECs—institution where situated

Netherlands

30 regional+1 central

Central REC—Minister of Health and Parliament
Regional REC—none

Poland

52+1 central

Central REC—none
Local RECs—central REC

Portugal

Several local+1 central

Central REC—Minister of Health
Local REC—institution where situated

Romania

1

Central REC—Ministry of Health

Slovakia

8 regional+ about 60 local+1 central

Central REC—Minister of Health
Local REC—Minister of Health

Slovenia

Several local+1 central

Central REC– none
Local REC—central REC

Spain

136

Local RECs—none

Sweden

6+1 central

Central REC—none
Regional RECs—none
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Ethical Committees in Italy
Historical milestones
The situation of ethics committees (ECs) in Italy
is at a critical point, because of a number of factors
emerging from new technical and scientific advances,
new legislative requirements and lack of harmonization of procedures. To look into the issue in greater
depth, it is important first to understand the establishment and organization of ethical committees in Italy.
The organization of ECs is quite different in Italy to
the rest of the EU. The first EC was created in 1973,
with the aim of ensuring that research for new medical
treatments was “for a person and with a person, never
on a person” (14). In the 1980s, there were few bodies in Italy that could be regarded as ECs (regionally,
in public bodies or in universities). It was only on 28th
March 1990 that the Italian National Bioethics committee was established, according to a decree signed by
the President of the Council of Ministers (15).
The Italian National Bioethics Committee (NBC)
The NBC consists of 40 members. including a
Chairman, two vice-Chairmen and experts from various
medical specialties such as biology, jurisprudence, psychology and philosophy. These members are appointed
for a period of three years, with membership being interdisciplinary and diverse, thus bringing together different experties on a single platform. The Committee
holds monthly plenary sessions and has five sub-committees focused on specific areas, dealing with bioethical
issues in the human genome and biotechnologies, artificial insemination, biomedicine, protection of critically
ill subjects, moral epistemology and bioethics training.
The tasks assigned to these committees are to give opinions, prepare legislative acts and address ethical and legal problems associated with the impact of scientific and
technological progress on human life. The NBC also
maintains relations with Ethics committees and legislative bodies at European and international levels (16).
Regulatory framework of Ethics Committees in Italy
A fundamental step for clinical regulation in Italy
was the implementation of good clinical practice in

the conduct of clinical trials on medicinal products for
clinical use (16). This was achieved through Legislative Decree No 211 of 24 June 2003 (the latest version
of the Helsinki Declaration, the Oviedo Convention,
good clinical practice standards and the guidelines on
the evaluation of the effectiveness of clinical trials updated by the European Agency for the Evaluation of
Medicinal Products). According to Article 2(1)(m) of
the Decree, an EC is “an independent body consisting
of healthcare professionals and non-medical members,
whose responsibility it is to protect the rights, safety and
wellbeing of human subjects involved in a trial and to
provide public assurance of that protection […]” (17).
Regional and local Ethics Committees
In last two decades, regional and national ECs
were established in Italy within hospitals, university
polyclinics, biomedical research bodies and institutions. According to Article 1 of Legislative Decree No
211 regarding clinical trials on medicinal products, the
ECs should verify the applicability of proposed trials
by critically evaluating their rationale, the relevance of
protocols (objectives, design, operation, result evaluation), the competence of researchers, and should assess
all ethical aspects, with respect to informed consent
while ensuring protection of privacy in the use of biological samples. Moreover, “The competence of each
Committee may concern, in addition to clinical trials
on medicinal products, any other issue they might be
entrusted with according to international practices,
namely the use of medicines and medical devices, surgical and clinical procedures or procedures related to
studies on food products on humans” (Law 8 November 2012, No. 189, Art. 12) (18).
The organizational structure of regional ECs is
represented by the Regions. Each Ethics Committee is in charge of one or more provinces, in order to
comply with the standard of one Committee per million inhabitants, without prejudice to the possibility of
providing an additional Ethics Committee, competent
to act in one or more scientific hospitalization and care
institutions (Law 8 November 2012, n. 189, Art. 5).
Some of the ECs have a national mandate that identifies their expertise in a particular area. Amongst these
are the Ethics Committees of the National Institute
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of Health (Istituto Superiore di Sanità, ISS) and the
“Celio” Military Hospital (Decision of Lazio Region
of June 12, 2013) (19).
Further developments in regional and National Ethics
committees in Italy
The latest EC guideline is the Ministerial Decree
of February 8, 2013 (20) which specifies that ECs are
independent bodies that ensure the rights, safety and
wellbeing of subjects enrolled in clinical trials, and
evaluate those trials on scientific, ethical and procedural
bases, thus guaranteeing public protection. Moreover,
this Decree allows the ECs to promote consultation on
ethical matters pertaining to scientific and clinical activities in the case where these have not been assigned
to any other specific bodies. Hence, the overall objective is to promote human values and to safeguard the
self-esteem and value of human subjects. In addition,
ECs can propose bioethics training for health professionals. Furthermore the legislation in 2014 (EU) No
536/2014 ; Article 8 (“Decision on the clinical trial”)
states that: “Each Member State concerned shall notify the sponsor through the EU portal as to whether the
clinical trial is authorised, whether it is authorised subject to conditions, or whether authorisation is refused,
notification shall be done by way of one single decision” (21). This resulted in a national debate on reducing the number of ECs. As a result, a gradual decline
in the number of ECs in Italy from 243 in 2012 to 91
in 2014 and 90 in 2019 (22) took place. Furthermore,
Law No 3 of 11 January 2018 (23) promoted a further
reduction in the number of ECs. Two decrees issued
by the Minister of Health following this law required
the identification of a maximum of 40 local ECs and 3
national ECs, of which one would be reserved for the
paediatric environment. However, implementing this
reform is difficult in practical terms, as legislation for
establishing local ECs and national ECs has still not
been enacted. A further provision of this law was the
establishment of an Italian Medicine Agency (AIFA)
and a National centre for the coordination of regional
ethics committees for clinical trials of medicines and
medical devices for human use (23).
Following an EU regulation, the NBC suggested
that CECs should be given legislative and administra-
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tive attention. A further Legislative Decree No 52 of
14 May 2019 was issued for the ‘Implementation of
the designated powers to review and reform the regulatory provisions in relation to clinical trials on medicinal products for human use, under Article 1(1) and (2)
of Law No 3 of 11 January 2018 (23)’. Certain provisions in this Decree might have a significant impact on
clinical trials. For instance, sponsors are permitted to
transfer data and results from non-profit trials for registration purposes. Until now, the use of data obtained
from non-profit trials for registration purposes has
been restricted. The sponsor or transferee is, however,
required to pay and to reimburse the direct and indirect costs incurred in the trial. Moreover, if the study is
further reclassified as profit-making, they have to pay
the corresponding charges, including any returns from
the exploitation of intellectual property. A Decree of
the Minister of Health was enacted on 31 October
2019 to stipulate measures intended to enable and support the performance of non-profit clinical trials and
observational studies, as well as to identify measures
for ensuring coordination between public and private
sponsors for clinical trials set up for post-marketing
surveillance of medicinal products. That Decree also
established an order, enacted by the AIFA, to identify
suitable procedures to assure the independence of clinical trials, ensuring that no conflict of interest should
arise in the assessment of subsequent applications.

Ethical guidelines for observational studies
In the health sciences, observational studies are
those studies in which an investigator considers the
variables of interest without his actions in any way
influencing the condition of the subject or subjects
studied. Observational studies are different from experimental studies, in the sense that in these studies no
intervention other than recording, classifying, counting and analysing of data takes place. In observational
studies the investigator has no control over the study
variables and merely observes outcomes. Most observational research is epidemiological or health services
research, but some observational studies, include case
series and case studies, are conducted by clinicians in
personal care settings (24).

Ethics committees

Observational studies can be classified into case
control studies, cohort studies, cross sectional studies,
case reports, case series, and descriptive studies which
add generalizable knowledge about health or disability
issues. These studies play an important role in ensuring the public interest in a safe environment and in safe
and effective health and support services. These studies
might examine the exposure of humans to chemicals in
the environment or to medicines resulting in diseases
and disorders. In addition, these studies are used to
identify any gaps in health and support service provision, and this obliges service providers to inform consumers that studies of this type are of utmost importance in improving the quality of the health and support
services. They should also give consumers details of the
measures taken to protect participants from harm (24).
Ethical requirements and regulations pertaining to
observational studies
Investigators conducting, or involved in conducting, observational studies are responsible for ensuring
that these studies meet ethical standards. Observational studies might or might not require informed
consent and rigorous EC review. When there is more
than one investigator, the principal investigator has
the overall responsibility for the ethics of the activity.
The ethical guidelines regarding observational studies
generally vary depending upon the type of study, and
might not be subject to EC review at all. For that reason clear guidelines for such studies are scarce. Currently, approval by ethics committee is mandatory for
all research in Canada, including the analysis of patient
records (25). However, no such requirement exists for
retrospective studies in, for example, Turkey (26).
Current legislative provisions in Italy pertaining
to observational studies are the following:
1) The Italian Ministry of Health circular n. 6,
2002, which defines non-interventional (observational) trials (27)
2) The Italian Legislative Decree n. 211/2003 on
clinical trials of medicinal products, which also gives
a definition of the “non-interventional” trial (observational study) (17)
3) The 20 March 2008 ruling of the Italian Drug
Agency (Agenzia Italiana del Farmaco, AIFA) which
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gives guidelines for the classification and conduct of
observational drug trials (28).
Since the publication of the first Italian legislation, as mentioned above, considerable attention has
been paid to defining and approving observational
studies by the clinical and epidemiological research
sector. Following the publication of these regulations,
a significant increase in the number of observational
(“non-interventional”) study protocols was submitted
to ethics committees for evaluation in Italy.
However, because there is no clear legislation in
this area from the EU, the ECs have difficulty in defining, interpreting and implementing existing regulations. Under EU human rights legislation, it can
be inferred that observational studies should ensure
respect for and protection of people participating in
these studies, with a fair distribution of the benefits
and burdens. The study should be designed in such a
manner that inclusion and exclusion criteria for participants are fair. There should not be any discrimination on the base of age, sex, disability or religious or
spiritual affiliation, except where it is essentially important to do so. Investigators should respect diversity
among participants, and conduct honest and thoughtful inquiry with rigorous analysis. Conflict of interest
should be avoided in the case of multidisciplinary and
multi-centre research.
Just as the registration of clinical trials has an ethical and scientific rationale, registering observational
studies at approved locations reduces duplication, ensures monitoring of projects with respect to ethical
guidelines, provides global access to and improves the
credibility of the information, and ensures transparency of research, thereby creating a knowledge bank.
However, observational studies are prone to publication and reporting bias due to lack of regulations regarding registration and reporting. Hence, registration
of these studies provides them with authenticity and
rationale (29,30).
Presently, ClinicalTrials.gov in Canada and US
(31,32) and the European Union electronic Register of
Post-Authorisation Studies (EU PAS Register) in the
EU are publicly available for the registration of postauthorisation studies, in order to improve the transparency of observational research (33). Over the past
few years, the number of observational studies regis-
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tered per year has increased, and observational studies
now represent about 15% of all studies on ClinicalTrials.gov. Approximately half of these studies are from
North America followed by Europe (20%) and Asia
(13%), where 85% of these are funded by non-industry
sources (31,34).
There is a considerable debate over the requirements of the EC committee for approval of observational studies. Some researchers are of the opinion that
EC review is not required because these studies are not
sensitive with respect to ethical concerns while, on the
other hand, other researchers emphasise the need for
EC review of each observational study. (35-38).
To harmonize the process of reporting of observational studies, in 2004, an international initiative, Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE), was launched.
STROBE provides complete guidelines on reporting
observational studies such as study design, participants, and results However, ethical requirements and
registration procedures are not addressed (39).
The International Committee of Medical Journal
Editors (ICMJE), along with specific international
journals, however, has clearly stated that submitting
publications based on observational studies requires
ethical approval, or at least a letter from an EC if ethical approval is not required (40-44).

Ethics in food research
With the increasing world population and extensive urbanization, the production of enough food
to feed everyone is a huge challenge, not only for
agriculture research and industry but also for food
and nutrition related research and industries. As this
area is directly related to the wellbeing and safety
of humans and involves the use of animals both for
research and as a food source, there are ethical concerns which are governed by relevant guidelines and
procedures (45,46). Food and nutrition research is a
diverse field with many aspects that raise ethical concerns such as research and development of new products and processes (e.g. GMOs), consumer behaviour,
health claims, supply chain, agricultural practices, food
safety and security, sustainability, regulation, trade and
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emergency food aid. Ethics plays an important role in
all these areas and frequently gives rise to questions
and challenges concerning issues and practices in food
related research. There are moral, cultural, social and
spiritual values related to the personalization of food
among various regions of the world, and this also results in ethical considerations when embarking on
food related research (47).
Risks to humans, animals and the environment
General ethical principles in food research are
the same as in other research arenas; they include personal safety and wellbeing, safeguarding the prestige
and honour of participating human subjects, ensuring
equal distribution of benefits, equity and justice, and
informing participants about harms which might arise
during experimental and non-experimental methods,
including observational studies, interviews, web-based
data collection (especially in the case of vulnerable
groups such as children), exposure of participants to
stressful and uncomfortable situations etc. In addition,
while designing the study, the researchers should give
thorough consideration to potential risks and to ethical issues related to society, animals and the environment, and should take necessary precautions to alleviate and avoid adverse effects.
In case of research involving animals, researchers should ensure animal welfare and the three Rs for
animal research i.e. replacement, reduction and refinement, to keep their suffering to a minimum. Cell and
tissue cultures should be used wherever possible, replacing animals. Endangered species or species at risk
should be avoided. Biotechnological research, particularly that involving GMOs, is of particular concern
with respect to threats to the environment. Research
in this area should be a balance between risk and benefits (47,48).
Ethical considerations in food research methodologies
and multidisciplinary research projects
Food research involves various methods. These
may encompass but are not limited to research, equivalent to medical research, which involves clinical trials to check the safety of food in human subjects with
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respect to allergies, nutrigenomics, and neuropsychology of food choice. Research involving medical interventions such as MRI and other technologies requires
critical ethical review. Human tissue samples might be
required in pharmacokinetics and pharmacodynamic
studies. In addition, observational studies involving
large groups of consumers require prior consent from
every participating individual. This could however potentially make the research impossible. This prior consent may not be required when research is being conducted in public places such as restaurants, canteens
and supermarkets. However, such researches need to
address the issues related to consumer privacy, and
this should be explained to both consenting and nonconsenting participants. On the other hand, research
carried out in private homes, small social and cultural
groups and hospitals requires rigorous prior informed
consent, data confidentiality and privacy protection.
In the case of identifiable data such as pictures, videos and audio recordings, informed consent should be
obtained in respect of release of data to third parties.
Where such consent is unavailable, participants should
not be subject to disclosure of identifiable data pertaining to themselves (46,47).
Studies involving covert research should only be
done where collecting data by any other methods is
impossible, where risks to participants are minimal,
and where anonymity is guaranteed. These projects
should undergo rigorous review by RECs. In addition
to observational and covert studies, technological advance has paved the way for utilization of social media for data collection in food related research. This
method might be of interest to people who want to
avoid face-to-face interviews. However, special ethical
consideration should be given to vulnerable groups like
children and teenagers. Other ethical concerns in this
regard arise in respect of recruitment, consent, privacy
and authenticity of the data (47).
Mostly, food related research is multicentre and
multidisciplinary. It is carried out in many countries,
and might include working in developing countries.
This requires the establishment of principles of equality and benefit to the local population, as well as the
assurance of biological diversity with respect to sharing of the benefits of genetic resources as food products and/or nutraceuticals. Specifically, when research

is carried out in hazardous situations, the health and
safety potential risks to researchers and local participants must be identified. In addition, security and confidentiality of data must be ensured (47,48).
Ethical concerns related to nutrigenomics, functional,
nano-based and genetically-modified (GM) foods
Nutrigenomics is based on the effect of nutrition on gene expression related to health. This helps
to identify the response of individuals to a particular
diet that allows personalization of dietary regimes in
order to obtain maximum health benefits thus leading
to the development of commercial functional foods. A
potential conflict may arise in this regard between the
requirements of genetic data and non-medical data.
Therefore, all types of data collection should be under strict ethical control. Furthermore, nanotechnology, nutrigenomics and genetic engineering, deployed
to develop functional consumer oriented foods that
require clinical trials, may give rise to various ethical
concerns such as health claim labelling (EU regulation No. 1924/ 2006) to ensure consumer satisfaction
in terms of safety and choice of foods. Based on ethical concepts and arising from misconceptions regarding nano-based and GM foods, these foods must be
labelled with a ‘clinically tested to be safe’ statement
(47-49).
Specifically, proper risk assessment of nano-based
foods should be conducted in terms of consideration
of potential health hazards such as biotoxicity and
bioaccumulation in human tissues. Therefore, checking the safety of such foods is of utmost importance.
Moreover, in the case of animal involvement in a study,
relevant ethical procedures should be implemented including the development of in vitro procedures wherever feasible.
Ethical issues in food security, sustainable food
production and distribution.
Food security legislation primarily focuses on ensuring sustainable production, distribution and marketing of food, in adequate amounts to make it physically, socially and economically accessible, in order to
meet the dietary requirements and food choices of all
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people of the world, and thereby to reduce hunger and
safeguard survival. However, despite efforts in this
field, approximately 900 million people are chronically
hungry and up to two billion suffer from intermittent
food insecurity. It is therefore necessary to consider the
ethical questions surrounding the integration of nutrition into the food security concept. Key ethical issues
include, but are not limited to, making societal decisions and defining values of food security that have an
impact on nutritional outcomes, and the ethical balance between environmental sustainability and meeting individual dietary and nutritional requirements. Issues related to overgrazing, extensive farming putting
animals at risk, use of alternative protein resources and
corresponding public acceptance issues make the situation even more cumbersome. Hence, such complex
issues should be given thorough consideration to ensure global food security (46-49).

EU’s new legislations and competitiveness of Italy
in Clinical Research
Good clinical practice and fair clinical trials are
integral components of health based research. In an
effort to simplify and standardize the rules and regulations of clinical trials across the EU, the European
Clinical Trials Directive 2001/20/CE (ECTD) was
introduced in 2001. The ECTD stressed good clinical
practice and ethical values, to ensure the safety of trial
participants (17).
Despite the fact that ECTD was an evolutionary
approach, it failed to achieve its aims, as each member
state was permitted to follow the ECTD guidelines
autonomously. That made room for contradictory decisions by competent local authorities. As a result, each
member state has its own procedures for submission
and processing of the proposals. It specifically affected
sponsors that aimed to conduct multicentre trials in
different member states, which obliged them to submit
different applications in different members states, and
sometimes in each centre (49,50). This considerably
increased the time required for processing and approval of applications and for conducting the trials. Besides
that, compulsory insurance cover for trials and higher
management costs led to a tremendous increase in the
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overall expenses of trials, making them unaffordable
for independent research organisations and not-forprofit institutes (50-52).
Consequently, the EU became less attractive for
the pharmaceutical market, thus significantly reducing the number of CTs (53-55). The situation became
even worse for Italy, which, despite being Europe’s
third largest bio-pharmaceutical market with outstanding research and leadership in the medical milieu, witnessed a marked decline in CTs. As a result
of the ECTD, a lack of interest from sponsors, scarcity of public funds for clinical trials and multiplicity
of Ethics Committees, there was a record decrease in
CTs (56,57). For instance, Italy recorded a 21% reduction in CTs from 2008 to 2012 (58). According to
EudraCT (EU clinical trial database), Italy’s share of
total projects registered in the US National Institute
of Health’s (NIH) database has decreased from 18.5%
in 2008 to 17.7% in 2012, in contrast to the rest of the
EU member states (59,60).
This decrease in registered multicentre trials
might be in part due to the cumbersome administrative procedures required for submission of documents,
review and approval of trials and signing of contracts
after approval of CTs by independent ECs. For instance, a survey was conducted on 134 Italian Independent ECs, for a single trial by Porcu et al., 2008
(61). This revealed that there is a huge variation in the
application procedures for CTs with respect to the
number and the format of required documents, with
the number of necessary documents ranging from 6
to 21, with 57% of the surveyed ECs requiring at least
one personalized document. The number of hard copies required ranged from 6 to 249, while 26.9% of ECs
demanded e-mail or CD-ROM submission (number
of copies ranging from 1 to 15) as well as the paper
version (61). This lack of harmonization in internal
procedures and guidelines was further reported by another study conducted in 2009 where a survey on the
practice of ethics committees in 10 European countries was conducted (62).
As per the EFGCP report (2012), this variation
in “centre-specific” documentation in Italy was largely
due, to the high number of Independent ECs. Italy
had the highest number of national, local and regional
ECs when compared to the rest of the EU member

Ethics committees

states. The high number of IECs resulted in a confusing situation, particularly for the acceptance or refusal
of an opinion. With respect to number of ECs. Italy
had 260 ethics committees, the United Kingdom had
120, Germany 50 and France only 25 (63).
Italy ranked last among nine EU countries with respect to the number of NIH-registered trials per capita
in a SAT-EU study conducted by Marta Gehring and
co-workers in 2015. This ranking was based on surveys
distributed to pharmaceutical companies, medical device manufacturers, Clinical Research Organizations
and academic Clinical Trial Units (CTUs) (64,65).
Italy scored low in all four of the criteria tested, i.e.
ranking 10th out of 12 countries in the availability of
trial-related information, 12th on the predictability and
speed of ECs/ IRBs, and 9th on the availability of required equipment. It ranked 7th out of 9 on its general
attractiveness as a place to conduct clinical trials. This
low score assigned by highly ranked market participants with decision making power in trial investments
is an alarming situation for a country with a history of
scientific excellence. With respect to the setting up of
multicentre trials, the participants were of the opinion
that the EC’s procedures and contracting processes in
Italy are so painstaking and sluggish, that, by the time
an international multicentre trial is under way, the Italian site could still be in process of setting up. That is
the main reason that, despite a desire to include Italy
in the conduct of CTs, they do not participate (66).
The study concluded that the reasons for this lack of
interest in CTs in Italy are the bureaucratic procedures, penalizing the high scientific level and research
standards of the Italian Investigators (67). This is more
apparent in the case of independent research organisations that usually takes longer to establish trials, have
limited financial resources, and involve professionals
who do not have the benefit of permanent employment contracts (67-70).
The SAT-EU Study Group suggested that the
implementation of simplified legislation governing
CTs, reduction in the number of ECs, consistency in
contracts and the establishment of qualified CTUs will
enhance international interest in setting up CTs, thus
improving the status of clinical research in Italy (64,66).
Nonetheless, the implementation of the ECTR (replacing ECTD; Regulation (EU) N.536/2014 of the

11

European Parliament and of the Council on clinical trials on medicinal products for human use’ adopted on 16
April 2014 (11)) that aims to speed up the application
process by centralizing, synchronizing and simplifying
the administrative documentation for multicentre CTs
across the EU, will definitely improve the situation in
member states (71). The new ECTR has very ambitious goals: to push Europe to be more competitive in
the CTs scenario, to improve transparency, to create
a simplified regulatory system and to increase public
trust (55,71).
Proper implementation of any ethical legislation
depends upon the awareness of the public in general
and concerned people (management staff, researchers,
reviewers, participants, ECs, investors etc) in particular. For instance, if researchers are not aware of the
rules and regulations regarding ethical issues pertaining to their research, they will not be able to meet the
requirements set by the ECs in line with national and
international standards. This will result in potential delays in obtaining opinions from the concerned ECs.
The same is the case regarding the proper utilization of
the benefits of ECTR.
Recently in a study, two separate surveys addressed
to Clinical Research coordinators (CRCs) and Clinical
Investigators (CI) were conducted by Cagnazzo et al.,
(2017) in an attempt to investigate the perception and
knowledge of the new regulations (ECTR) by Italian
professionals (72). The study highlighted that the institutional channels and the managements of Hospitals/Institutes are not taking appropriate measures to
inform clinical researchers about the ECTR, and neither have they documented plans to do so; acquiring
this information is still very much a personal initiative of the researchers. Moreover, they highlighted that
slow bureaucracy, inadequate English language skills
and low susceptibility to change accounts for Italy being not ready to accommodate changes brought by
ECTR (72).

Role of internal ethics committees in expediting the
approval process of a research project
Be it clinical research, an observational study, food
science and nutrition or biotechnological research, the
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potential harm to human subjects and to animals in
particular, and to the overall environment in general
has necessitated the development of certain ethical
guidelines to ensure that a project is conducted according to national and international ethical standards.
However, implementation of these guidelines, policies
and procedures begins at the investigator and researcher level. In most cases, potential delays in obtaining an
opinion on a particular project from the responsible
EC are in part due to inappropriate documentation,
which in turn is due to lack of knowledge and experience in addressing the ethical issues (73,74). Setting up
an internal institutional ethics committee (IEC) holds
promise here for not-for-profit organizations, as these
internal committees could provide initial feedback on
research proposals. This would help them to address
critical ethical issues prior to the submission of proposals to regional/ local or national ECs, thus considerably reducing the time taken for obtaining a positive
opinion, and saving funds and energy. However, this
does not necessarily guarantee approval of proposals
by ECs (74). In addition, internal ethics committees
can advise on the training of investigators with respect
to ethical issues in their field of research.
However, to really get the benefits of an IEC,
the organization should ensure that it is comprised
of trained individuals that are familiar with research
settings. This would not only help them to guide the
investigators/ researchers in the preparation of project
proposals but would also enable monitoring of ongoing research projects. This would in turn help the institution to identify potential gaps in implementing
policies and procedures, and to impose sanctions for
violations by investigators. However, the risks associated with these committees are the potential occurrence of conflicts of interest, and the personal likes and
dislikes of members (75,76). Studies related to evaluation of the role of IECs are scarce. Further studies
in this regard might prove useful in determining their
efficacy in non-for-profit institutions in implementing
institutional, national and international ethical policies
and guidelines in the preparation of research proposals, and also in the conduct of research that might raise
ethical concerns regarding safety, wellbeing and rights
of human subjects in particular, of experimental animals and the overall environment in general.
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Conclusion
Ethical approval of research projects, observational studies and clinical trials is necessary in order
to safeguard human rights and wellbeing, and to avoid
potential harm to society, religious groups, vulnerable
subjects and animals. Ethical review of research projects improves the scientific quality and authenticity of
research. However, considerable difficulties are faced
by investigators and investors in the process of getting approval for setting up clinical trials or food related research, and this has potentially hampered the
progress of this kind of research in countries having
multiple regulator ECs at various levels. This necessitates the need for reduction in the number of ECs,
improvement of the rules and regulations for ethical
requirements in food related research, observational
and epidemiological studies, and simplification and
standardisation of the procedures for the submission
of multicentre and interdisciplinary research projects.
Administrative procedures in the approval and
setting up of trials are compromising Italy’s reputation
for high scientific standards in medicine and clinical
research. Implementation of simplified legislation governing clinical trials, reduction in the number of ECs,
standardisation of contracts, and improvement of trials
management through adequate clinical trials units, can
encourage clinical research in Italy.
In addition, review of research proposals prior to
submission by internal institutional ethics committees
holds the promise of reducing the time duration required for the processing of proposals. However, this
does not guarantee a positive outcome from an EC
committee review. Reduction in the number of ECs,
centralization of submission procedures and further
studies evaluating the efficacy of internal ethical committees in setting up and conducting clinical trials in Italy might help in simplifying ethical review procedures
and enhancing Italy’s competitiveness with respect to
the global market for clinical research. The main problem in Italy and Europe is the lack of common legislation that would coordinate all the European countries
in the same manner. Furthermore, there are difficulties
in the interactions among countries located in different continents due to the high lack of homogeneity
among systems. Finally, we took the Italian model as
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an example, because an international committee based
in Italy is going to be established for the laboratory
EBTNA-LAB. In the future, we will produce other
works and publications in order to address other issues
regarding ethics committees.
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